Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.
This activity is intended for hematologists/oncologists, pulmonologists, pathologists, nurses, and pharmacists.
The goal of this activity is to improve knowledge regarding recent clinical trial data on the use of immune checkpoint inhibitors (ICIs) alone or in combination in advanced lung cancers.
Learning Objectives:
- Have increased knowledge regarding the emerging clinical trial data on the use of ICIs alone or in combination with other cancer immunotherapies in the management of advanced lung cancers
- Have increased knowlege regarding the impact of recent clinical data on treatment strategies for patients with advanced lung cancers in the community oncology setting
Approximate Time to Complete: 45 minutes
Credit Available: Dec. 26, 2019 - Dec. 26, 2020
Developed through a partnership between SITC and Medscape.
 |
|
"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)